Back to search
FDAFDA · Food and drugs·Recall number D-1545-2022

Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Suspension, Manufactured by: Cipla Ltd., India, Manufactured for Cipla USA Inc., Warren NJ, NDC# 69097-318-86.

Published October 5, 2022 · Recall initiated: September 15, 2022

Summary

FDA records drug Class II recall D-1545-2022, published October 5, 2022 and initiated September 15, 2022. Recalling firm: CIPLA; Status: Terminated; Reported quantity: 641,160 ampules; Lot: Lot #s: GA20080, GA20081, GA20094, Exp. 01/2024. Class II means possible temporary or medically reversible effects, or a remote probability of serious health consequences.

Status when published: Terminated — openFDA updates weekly, so this field may not reflect the current status. Always confirm with the official notice.

What's the hazard

Lack of Assurance of Sterility

What to do

Voluntary: Firm initiated · Letter

Get an email if BUDESONIDE has another recall

Free. We only write when there's a new recall that matches. Unsubscribe in one click.

Recall details

Brand
BUDESONIDE
Manufacturer
CIPLA
Distributor
Nationwide in the USA and Puerto Rico
Lot
Lot #s: GA20080, GA20081, GA20094, Exp. 01/2024
Risk classification
Class II
Area (FDA)
drug
Country
United States

Related recalls

Questions about this recall

Was Budesonide Inhalation Suspension 0.25mg/2mL, For Inhalation Only, Rx Only, 1 envelope x five 2 mL Single Dose Ampules per pouch, Sterile Suspension, Manufactured by: Cipla Ltd., India, Manufactured for Cipla USA Inc., Warren NJ, NDC# 69097-318-86. recalled?

Yes. FDA published recall D-1545-2022 on October 5, 2022. Reported hazard: Lack of Assurance of Sterility

What should I do if I have this product?

Voluntary: Firm initiated · Letter

How do I know if my unit is part of the recall?

Compare your product details with the notice. Brand: BUDESONIDE.